Why Madrigal Pharmaceuticals Stock Is Soaring Today

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain came after the small biopharmaceutical company announced its fourth-quarter and full-year 2024 results before the market opened.Madrigal reported fourth-quarter revenue of $103.3 million, all of which stemmed from sales of Rezdiffra, the first drug approved for treating metabolic dysfunction-associated steatohepatitis (MASH). The company posted a net loss in Q4 of $59.4 million, or $2.71 per share. Those results blew past consensus Wall Street expectations. The average analyst's estimate was for Q4 revenue of $87.7 million and a net loss of $4.48 per share. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool